Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AKTi-treated TIL in metastatic melanoma
NCT02489266Phase 1Withdrawn
- Sponsor
- National Cancer Institute
- Start
- Jun 2015
- Primary completion
- Jun 2016
- Modality
- Adoptive Cell Transfer
01
Overview
Phase 1, open-label trial of AKTi-treated tumor-infiltrating lymphocytes in melanoma, sponsored by National Cancer Institute. Planned start Jun 2015; status: withdrawn.
02
Drugs
AKTi-treated tumor-infiltrating lymphocytes
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT02489266.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02489266.